<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Rezolute Inc — News on 6ix</title>
    <link>https://6ix.com/company/rezolute-inc</link>
    <description>Latest news and press releases for Rezolute Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/rezolute-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835bc6a78dffbe2df116c48.webp</url>
      <title>Rezolute Inc</title>
      <link>https://6ix.com/company/rezolute-inc</link>
    </image>
    <item>
      <title>Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-to-present-results-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-at-the-pediatric-endocrine-society-pes-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-to-present-results-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-at-the-pediatric-endocrine-society-pes-annual-meeting</guid>
      <pubDate>Tue, 21 Apr 2026 11:00:00 GMT</pubDate>
      <description>Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that results from the Phase 3 sunRIZE study of ersodetug in congenital HI were accepted for an oral presentation at the Pediatric Endoc</description>
    </item>
    <item>
      <title>Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting</guid>
      <pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
      <description>FDA encourages the Company to submit comprehensive data from sunRIZE and the ongoing open-label extension to inform next steps for the program REDWOOD CITY,</description>
    </item>
    <item>
      <title>Rezolute to Participate in the Citizens Life Sciences Conference</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-to-participate-in-the-citizens-life-sciences-conference-7</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-to-participate-in-the-citizens-life-sciences-conference-7</guid>
      <pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company</description>
    </item>
    <item>
      <title>Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-reports-second-quarter-fiscal-210500232</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-reports-second-quarter-fiscal-210500232</guid>
      <pubDate>Thu, 12 Feb 2026 21:05:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended December 31, 2025. Congenital Hyperinsulinism (HI) In December 2025, Rezolute reported topline results from sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-contr</description>
    </item>
    <item>
      <title>Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-participate-guggenheim-emerging-outlook-biotech-summit-2026-2026-02-04</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-participate-guggenheim-emerging-outlook-biotech-summit-2026-2026-02-04</guid>
      <pubDate>Wed, 04 Feb 2026 05:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused</description>
    </item>
    <item>
      <title>Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-provides-insights-its-phase-3-sunrize-study-congenital-hyperinsulinism-and</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-provides-insights-its-phase-3-sunrize-study-congenital-hyperinsulinism-and</guid>
      <pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
      <description>Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to</description>
    </item>
    <item>
      <title>Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-announces-phase-3-sunrize-study-results-congenital-hyperinsulinism-2025-12</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-announces-phase-3-sunrize-study-results-congenital-hyperinsulinism-2025-12</guid>
      <pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
      <description>Study did not meet the primary or key secondary endpoint 45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40%</description>
    </item>
    <item>
      <title>Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2025-11-10</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2025-11-10</guid>
      <pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company</description>
    </item>
    <item>
      <title>Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-reports-first-quarter-fiscal-2026-financial-results-and-provides-business</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-reports-first-quarter-fiscal-2026-financial-results-and-provides-business</guid>
      <pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused</description>
    </item>
    <item>
      <title>Rezolute to Host Virtual Investor Event on Ersodetug Development Program</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-host-virtual-investor-event-ersodetug-development-program-2025-11-05</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-host-virtual-investor-event-ersodetug-development-program-2025-11-05</guid>
      <pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
      <description>Webcast scheduled for Monday, November 10 at 12:00 pm EST REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or</description>
    </item>
    <item>
      <title>Rezolute to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-participate-upcoming-investor-conferences-2025-10-15</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-participate-upcoming-investor-conferences-2025-10-15</guid>
      <pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused</description>
    </item>
    <item>
      <title>Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-reports-fourth-quarter-and-full-year-fiscal-2025-financial-results-and</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-reports-fourth-quarter-and-full-year-fiscal-2025-financial-results-and</guid>
      <pubDate>Wed, 17 Sep 2025 04:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company</description>
    </item>
    <item>
      <title>Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-announces-alignment-fda-streamlined-design-ongoing-phase-3-trial-ersodetug</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-announces-alignment-fda-streamlined-design-ongoing-phase-3-trial-ersodetug</guid>
      <pubDate>Tue, 02 Sep 2025 04:00:00 GMT</pubDate>
      <description>Open-label study in as few as 16 tumor hyperinsulinism (HI) patients Study initiated and enrolling patients in the U.S. and Europe Topline data expected in</description>
    </item>
    <item>
      <title>Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-appoints-seasoned-commercial-executive-sunil-karnawat-chief-commercial</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-appoints-seasoned-commercial-executive-sunil-karnawat-chief-commercial</guid>
      <pubDate>Wed, 20 Aug 2025 04:00:00 GMT</pubDate>
      <description>Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug REDWOOD CITY, Calif., Aug. 20,</description>
    </item>
    <item>
      <title>XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements</title>
      <link>https://6ix.com/company/rezolute-inc/news/xoma-royalty-reports-second-quarter-and-year-to-date-2025-financial-results-and-highlights-recent-business-achievements</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/xoma-royalty-reports-second-quarter-and-year-to-date-2025-financial-results-and-highlights-recent-business-achievements</guid>
      <pubDate>Wed, 13 Aug 2025 11:30:00 GMT</pubDate>
      <description>Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently announced acquisition of LAVA Therapeutics. Company acquisitions: Announced XOMA Royalty’s acquisitions of Turnstone Biologics, LAVA Therapeutics, and HilleVax; acted as structuring agent and provided financing for XenoTherapeutics’ acquisition of ESSA Pharma; completed the sale of K</description>
    </item>
    <item>
      <title>Rezolute to Participate in the BTIG Virtual Biotechnology Conference</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-participate-btig-virtual-biotechnology-conference-2025-07-22</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-participate-btig-virtual-biotechnology-conference-2025-07-22</guid>
      <pubDate>Tue, 22 Jul 2025 04:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused</description>
    </item>
    <item>
      <title>Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-announces-presentation-participant-baseline-data-its-fully-enrolled-phase-3</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-announces-presentation-participant-baseline-data-its-fully-enrolled-phase-3</guid>
      <pubDate>Wed, 09 Jul 2025 04:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused</description>
    </item>
    <item>
      <title>Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-announces-completion-enrollment-phase-3-sunrize-study-ersodetug-patients</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-announces-completion-enrollment-phase-3-sunrize-study-ersodetug-patients</guid>
      <pubDate>Wed, 28 May 2025 04:00:00 GMT</pubDate>
      <description>Target enrollment exceeded with 62 participants enrolled, including approximately 15 percent from U.S. sites Topline data is anticipated in December of 2025</description>
    </item>
    <item>
      <title>Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-reports-third-quarter-fiscal-2025-financial-results-and-provides-business</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-reports-third-quarter-fiscal-2025-financial-results-and-provides-business</guid>
      <pubDate>Tue, 13 May 2025 04:00:00 GMT</pubDate>
      <description>sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug</description>
    </item>
    <item>
      <title>Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism</title>
      <link>https://6ix.com/company/rezolute-inc/news/rezolute-receives-breakthrough-therapy-designation-fda-ersodetug-treatment-0</link>
      <guid isPermaLink="true">https://6ix.com/company/rezolute-inc/news/rezolute-receives-breakthrough-therapy-designation-fda-ersodetug-treatment-0</guid>
      <pubDate>Mon, 05 May 2025 04:00:00 GMT</pubDate>
      <description>Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year Designation underscores need for therapies to treat severe</description>
    </item>
  </channel>
</rss>